Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan: An Epidemiological Study Based on a National Administrative Database

Clinical and Applied Thrombosis/Hemostasis

Volumn 22, Issue 1, 2016, Pages 21-27

  Murata, Atsuhiko ^a   Okamoto, Kohji ^b   Mayumi, Toshihiko ^c   Muramatsu, Keiji ^a   Matsuda, Shinya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Yahata Municipal Hospital   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

administrative database; disseminated intravascular coagulation; hospital factors; recombinant human soluble thrombomodulin; time trend

Indexed keywords

ANTITHROMBIN; HEPARIN; PROTEINASE INHIBITOR; RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN; THROMBOMODULIN; UNCLASSIFIED DRUG; THBD PROTEIN, HUMAN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEALTH CARE SYSTEM; HUMAN; JAPAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; DISSEMINATED INTRAVASCULAR COAGULATION; EPIDEMIOLOGY; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEPARIN; HUMANS; JAPAN; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RISK FACTORS; SURVIVAL RATE; THROMBOMODULIN;

EID: 84951336287     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029615575072     Document Type: Article

References (28)

1. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004; 2 (11): 1924-1933.
2. Madoiwa S, Nunomiya S, Ono T, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006; 84 (5): 398-405.
3. Dalainas I,. Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: a literature review. Eur Rev Med Pharmacol Sci. 2008; 12 (1): 19-31.
4. Nakagawa M, Tsuji H,. Current trends in the diagnosis of disseminated intravascular coagulation in Japan: findings of questionnaire survey. Rinsho Ketsueki. 1999; 40 (5): 362-364.
5. Gogos CA, Lekkou A, Papageorgiou O, et al. Clinical prognostic markers in patients with severe sepsis: a prospective analysis of 139 consecutive cases. J Infect. 2003; 47 (4): 300-306.
6. Cartin-Ceba R, Kojicic M, Li G, et al. Epidemiology of critical care syndromes, organ failures, and life-support interventions in a suburban US community. Chest. 2011; 140 (6): 1447-1455.
7. Wada H, Asakura H, Okamoto K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010; 125 (1): 6-11.
8. Nishiyama T, Matsukawa T, Hanaoka K,. Is protease inhibitor a choice for the treatment of pre-or mild disseminated intravascular coagulation? Crit Care Med. 2000; 28 (5): 1419-1422.
9. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006; 4 (1): 90-97.
10. Ito T, Maruyama I,. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011; 9 (suppl 1): 168-173.
11. Murata A, Matsuda S,. Association between ambulance distance to hospitals and mortality of acute diseases in Japan: national database analysis. J Public Health Manag Pract. 2013; 19 (5): e23-e28.
12. Murata A, Okamoto K, Muramatsu K, et al. Effects of additional laparoscopic cholecystectomy on outcomes of laparoscopic gastrectomy in patients with gastric cancer based on a national administrative database. J Surg Res. 2014; 186 (1): 157-163.
13. Murata A, Muramatsu K, Ichimiya Y, Kubo T, Fujino Y, Matsuda S,. Endoscopic submucosal dissection for gastric cancer in elderly Japanese patients: an observational study of financial costs of treatment based on a national administrative database. J Dig Dis. 2014; 15 (2): 62-70.
14. Murata A, Okamoto K, Muramatsu K, Matsuda S,. Time trend of medical economic outcomes of endoscopic submucosal dissection for gastric cancer in Japan: a national database analysis. Gastric Cancer. 2014; 17 (2): 294-301.
15. Murata A, Okamoto K, Muramatsu K, Matsuda S,. Endoscopic submucosal dissection for gastric cancer: the influence of hospital volume on complications and length of stay. Surg Endosc. 2014; 28 (4): 1298-1306.
16. 2 emissions in the residential sector in Japan-Case study of Iwate prefecture. Appl Energy. 2008; 85 (4): 204-217.
17. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007; 5 (1): 31-41.
18. Yamakawa K, Fujimi S, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011; 15 (3): R123.
19. Kawano N, Yoshida S, Ono N, et al. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution. J Clin Exp Hematop. 2011; 51 (2): 101-107.
20. Jones MI, Greenfield SM, Bradley CP,. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ. 2001; 323 (7309): 378-381.
21. Wen YW, Huang WF, Lee YC, Kuo KN, Tsai CR, Tsai YW,. Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of thiazolidinediones for diabetes. BMC Health Serv Res. 2011; 11: 21.
22. Garjón FJ, Azparren A, Vergara I, Azaola B, Loayssa JR,. Adoption of new drugs by physicians: a survival analysis. BMC Health Serv Res. 2012; 12: 56.
23. Di Nisio M, Baudo F, Cosmi B, et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012; 129 (5): e177-e184.
24. Levi M, Toh CH, Thachil J, Watson HG,. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009; 145 (1): 24-33.
25. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2014; 11 (4): 761-767.
26. Wada H, Okamoto K, Iba T, et al.Japanese Society of Thrombosis Hemostasis/DIC Subcommittee. Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". Thromb Res. 2014; 134 (4): 924-925.
27. Desirajua R, Nair bH, Chintagunta P,. Diffusion of new pharmaceutical drugs in developing and developed nations. Intern J Res Mark. 2004; 21 (4): 341-357.
28. Martí-Carvajal AJ, Simancas D, Cardona AF,. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database Syst Rev. 2011;(6): CD008562.